DCs have major histocompatibility complex (MHC) I and II molecules that present tumor peptide antigens to T cells with costimulation by the B7 molecule, resulting in the efficient activation of T-cell responses against cancer antigens, which is called the priming phase (step 2 to 3). Here, CD80 is linked to cancer.